162 related articles for article (PubMed ID: 25287191)
21. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
22. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment.
Yarovoi HV; Kufrin D; Eslin DE; Thornton MA; Haberichter SL; Shi Q; Zhu H; Camire R; Fakharzadeh SS; Kowalska MA; Wilcox DA; Sachais BS; Montgomery RR; Poncz M
Blood; 2003 Dec; 102(12):4006-13. PubMed ID: 12881300
[TBL] [Abstract][Full Text] [Related]
23. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies.
Shi Q; Wilcox DA; Fahs SA; Weiler H; Wells CW; Cooley BC; Desai D; Morateck PA; Gorski J; Montgomery RR
J Clin Invest; 2006 Jul; 116(7):1974-82. PubMed ID: 16823491
[TBL] [Abstract][Full Text] [Related]
24. Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A.
Cai Y; Shi Q
Front Immunol; 2020; 11():964. PubMed ID: 32595633
[TBL] [Abstract][Full Text] [Related]
25. In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.
Greene TK; Wang C; Hirsch JD; Zhai L; Gewirtz J; Thornton MA; Miao HZ; Pipe SW; Kaufman RJ; Camire RM; Arruda VR; Kowalska MA; Poncz M
Blood; 2010 Dec; 116(26):6114-22. PubMed ID: 20852129
[TBL] [Abstract][Full Text] [Related]
26. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response.
Ozelo MC; Vidal B; Brown C; Notley C; Hegadorn C; Webster S; Harpell L; Ahlin J; Winterborn A; Handforth J; Arruda VR; Hough C; Lillicrap D
Blood; 2014 Jun; 123(26):4045-53. PubMed ID: 24829206
[TBL] [Abstract][Full Text] [Related]
27. Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.
Shi Q; Kuether EL; Chen Y; Schroeder JA; Fahs SA; Montgomery RR
Blood; 2014 Jan; 123(3):395-403. PubMed ID: 24269957
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
29. Sustaining expression of B domain-deleted human factor VIII mediated by using lentiviral vectors in NOD/SCID mouse.
Li YJ; Chen C; Zeng LY; Cao J; Xu KL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):658-63. PubMed ID: 22739177
[TBL] [Abstract][Full Text] [Related]
30. Efficient expression of a transgene in platelets using simian immunodeficiency virus-based vector harboring glycoprotein Ibalpha promoter: in vivo model for platelet-targeting gene therapy.
Ohmori T; Mimuro J; Takano K; Madoiwa S; Kashiwakura Y; Ishiwata A; Niimura M; Mitomo K; Tabata T; Hasegawa M; Ozawa K; Sakata Y
FASEB J; 2006 Jul; 20(9):1522-4. PubMed ID: 16723382
[TBL] [Abstract][Full Text] [Related]
31. Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.
Shi Q; Fahs SA; Kuether EL; Cooley BC; Weiler H; Montgomery RR
Blood; 2010 Oct; 116(16):3049-57. PubMed ID: 20606161
[TBL] [Abstract][Full Text] [Related]
32. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
33. Ectopic platelet-delivered factor (F) VIII for the treatment of Hemophilia A: Plasma and platelet FVIII, is it all the same?
Greene TK; Lambert MP; Poncz M
J Genet Syndr Gene Ther; 2011 Nov; Suppl 1(1):. PubMed ID: 24319630
[TBL] [Abstract][Full Text] [Related]
34. Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of
Zhao J; Zhou M; Wang Z; Wu L; Hu Z; Liang D
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054807
[TBL] [Abstract][Full Text] [Related]
35. Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.
Staber JM; Pollpeter MJ; Anderson CG; Burrascano M; Cooney AL; Sinn PL; Rutkowski DT; Raschke WC; McCray PB
Gene Ther; 2017 Nov; 24(11):742-748. PubMed ID: 28905885
[TBL] [Abstract][Full Text] [Related]
36. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
Lei TC; Scott DW
Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
[TBL] [Abstract][Full Text] [Related]
37. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
38. Platelets as delivery systems for disease treatments.
Shi Q; Montgomery RR
Adv Drug Deliv Rev; 2010 Sep; 62(12):1196-203. PubMed ID: 20619307
[TBL] [Abstract][Full Text] [Related]
39. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
[TBL] [Abstract][Full Text] [Related]
40. Altered cleavage of human factor VIII at the B-domain and acidic region 3 interface enhances expression after gene therapy in hemophilia A mice.
Nguyen GN; Lindgren JR; Seleme MC; Kafle S; Zander CB; Zheng XL; Sabatino DE
J Thromb Haemost; 2023 Aug; 21(8):2101-2113. PubMed ID: 37080538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
